Pharma BD Deal Intelligence
Bayer to acquire Merck's consumer care business for $14.2 billion, gaining global number two position in non-prescription medications.
Bayer becomes a top OTC player after $14.2B deal with Merck, adding Claritin, Coppertone and Dr. Scholl's brands to its portfolio.
Merck and Bayer announced that their investigational drug vericiguat met its primary endpoint in the Phase III VICTORIA trial in patients with worsening…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer AG agreed to acquire Merck & Co.'s Consumer Care (MCC) business for $14.2 billion in an all-cash asset divestiture. The transaction included global trademark and prescription rights for Claritin, Afrin, Coppertone, Dr. Scholl's, and other OTC brands. Announced May 6, 2014; closed October 1, 2014.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Merck & Co. Inc. (this deal) | 2014 | $14.2B | 56 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2014 deals · Bayer AG deals · Cardiovascular deals